Table 3 Patient information for predominant histological subtypes in pathological stage I
Total | Group A (AIS + MIA) | Group B (Lepidic) | Group C (Papillary + acinar + variant) | Group D (Solid + micropapillary) | p-value | ||
|---|---|---|---|---|---|---|---|
n | 2165 | 304 | 469 | 1242 | 150 | ||
Sex (male/Female), n (%) | 1,058/1,107 | 119/185 (39.1%) | 199/270 (42.4%) | 635/608 (51.1%) | 98/52 (65.3%) | < 0.001 | |
Age, mean ± SD | 66.76 ± 9.02 | 66.49 ± 9.67 | 67. 65 ± 8.18 | 66.55 ± 9.13 | 66.19 ± 9.23 | 0.201 | |
Smoking history ( ±), n (%) | 1046/1060 (49.7%) | 110/187 (37.0%) | 188/269 (41.1%) | 642/563 (53.3%) | 106/41 (72.1%) | < 0.001 | |
Operation time (min.), mean ± SD | 201.1 ± 64.30 | 203.47 ± 62.70 | 195.27 ± 64.24 | 203.56 ± 65.35 | 194.17 ± 57.46 | 0.028 | |
Invasion, n (%) | |||||||
Lymphatic vessel invasion ( ±) | 371/1566 (19.2%) | 0/265 (0.0%) | 52/383 (12.0%) | 277/823 (25.2%) | 42/95 (30.7%) | < 0.001 | |
Vascular invasion ( ±) | 350/1593 (18.0%) | 0/267 (0.0%) | 36/400 (8.3%) | 248/853 (22.5%) | 66/73 (47.5%) | < 0.001 | |
Pleural invasion ( ±) | 383 /1770 (17.8%) | 0/301 (0.0%) | 51/416 (10.9%) | 291/944 (23.6%) | 41/109 (27.3%) | < 0.001 | |
EGFR mutation ( ±) | 459/498 (48.0%) | 64/42 (60.4%) | 102/74 (58.0%) | 284/325 (46.6%) | 9/57 (13.6%) | < 0.001 | |
Adjuvant therapy ( ±) | 563/1587 (26.2%) | 24/278 (7.9%) | 116/349 (24.9%) | 378/857 (30.6%) | 45/103 (30.4%) | < 0.001 | |
Pathological stage IA/IB | 1431/734 (66.1%) | 281/23 (92.4%) | 319/150 (68.0%) | 749/493 (60.3%) | 82/68 (54.7%) | < 0.001 | |